A5020

Prohibits pharmacy benefit manager from using spread pricing as model of prescription drug pricing; requires transparency in provision of pharmacy benefits management services.

Introduced·5/7/26
Introduced Text

New Jersey A5020 bans spread pricing by pharmacy benefit managers and mandates transparency in their services.

New Jersey A5020 prohibits pharmacy benefit managers from using spread pricing in their contracts with carriers, health benefits plans, and pharmacies. Spread pricing occurs when the contracted price for prescription drugs differs from the amount paid to pharmacies. The bill mandates that pharmacy benefit managers remit 100 percent of rebates, fees, discounts, and other remuneration to the carrier, health benefits plan, or purchaser.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Financial Institutions and Insurance Committee
Next
Committee decision

Sponsors

DD
2
0
Democratic CaucusRepublican Caucus

History

May 7

Assembly

Introduced, Referred to Assembly Financial Institutions and Insurance Committee